NanoViricides Inc. (NNVC.OB) Announces Significant Results in its Anti-HIV Studies
In 1981, the United States became the first country to identify HIV/AIDS as a distinct condition. Since then, hundreds of thousands of people have become infected, and more than 500,000 have died from the HIV/AIDS virus. It’s a race to arms, as facilities throughout the world conduct studies to combat the virus. NanoViricides Inc. (OTCBB: NNVC) is one such company. Today the company announced that its anti-HIV drug candidates have demonstrated significant therapeutic efficacy in recent preliminary animal studies at a Bio-Safety Level 3 Laboratory facility in Boston, Mass. The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS,…